TY - JOUR
T1 - Targeting angiogenesis in advanced cervical cancer
AU - Eskander, Ramez N.
AU - Tewari, Krishnansu S.
N1 - Funding Information:
The research was supported by a National Cancer Institute T32 Training Grant awarded to the Division of Gynecologic Oncology at the University of California, Irvine.
Funding Information:
K.S.T discloses that he has served as a consultant for Genentech/Roche and his institution has been awarded a research grant from Genentech for contracted research.
PY - 2014/11
Y1 - 2014/11
N2 - Patients with advanced stage or recurrent cervical cancer represent a population with limited chemotherapeutic options. More specifically, patients with recurrent disease have a poor salvage rate, with a 5-year survival rate of less than 10%. This year, the first prospective phase III clinical trial exploring the anti-angiogenic agent, bevacizumab, was published, meeting its primary endpoint, with a significant improvement in overall survival. As such, a review of anti-angiogenic therapy in the treatment of this disease is warranted.
AB - Patients with advanced stage or recurrent cervical cancer represent a population with limited chemotherapeutic options. More specifically, patients with recurrent disease have a poor salvage rate, with a 5-year survival rate of less than 10%. This year, the first prospective phase III clinical trial exploring the anti-angiogenic agent, bevacizumab, was published, meeting its primary endpoint, with a significant improvement in overall survival. As such, a review of anti-angiogenic therapy in the treatment of this disease is warranted.
KW - angiogenesis
KW - bevacizumab
KW - cervical cancer
UR - https://www.scopus.com/pages/publications/84910029185
U2 - 10.1177/1758834014543794
DO - 10.1177/1758834014543794
M3 - Review article
C2 - 25364393
AN - SCOPUS:84910029185
SN - 1758-8340
VL - 6
SP - 280
EP - 292
JO - Therapeutic Advances in Medical Oncology
JF - Therapeutic Advances in Medical Oncology
IS - 6
ER -